Arvinas, Inc. Files 8-K: Exit Costs, Reg FD, Other Events

TL;DR

ARVN filing 8-K: Exit costs, Reg FD, other events. Watch for financial impact.

AI Summary

On September 17, 2025, Arvinas, Inc. filed an 8-K report detailing cost associated with exit or disposal activities, a Regulation FD disclosure, and other events. The filing also includes financial statements and exhibits, indicating potential restructuring or strategic changes within the company.

Why It Matters

This filing suggests Arvinas may be undergoing significant operational changes, potentially impacting its financial structure and future strategic direction.

Risk Assessment

Risk Level: medium — The filing indicates potential restructuring or disposal activities, which can introduce financial and operational risks.

Key Players & Entities

• Arvinas, Inc. (company) — Registrant
• September 17, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share ARVN The Nasdaq Stock Market
• $4.5 million — xpects that it will incur approximately $4.5 million in costs in connection with the workfor
• $100 million — ase program for the repurchase of up to $100 million of the currently outstanding shares of

Filing Documents

• arvn-20250917.htm (8-K) — 40KB
• arvnstrategicupdaterelea.htm (EX-99.1) — 18KB
• arvnstrategicupdaterelea001.jpg (GRAPHIC) — 218KB
• arvnstrategicupdaterelea002.jpg (GRAPHIC) — 264KB
• arvnstrategicupdaterelea003.jpg (GRAPHIC) — 235KB
• arvnstrategicupdaterelea004.jpg (GRAPHIC) — 285KB
• arvnstrategicupdaterelea005.jpg (GRAPHIC) — 276KB
• arvnstrategicupdaterelea006.jpg (GRAPHIC) — 33KB
• 0001655759-25-000147.txt ( ) — 1992KB
• arvn-20250917.xsd (EX-101.SCH) — 2KB
• arvn-20250917_lab.xml (EX-101.LAB) — 23KB
• arvn-20250917_pre.xml (EX-101.PRE) — 13KB
• arvn-20250917_htm.xml (XML) — 3KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On September 17, 2025, management of Arvinas, Inc. (the "Company'), pursuant to authority delegated by the Board of Directors of the Company (the "Board"), committed to and approved a reduction in workforce of approximately 15% across roles in functional areas of the Company primarily related to vepdegestrant commercialization. The Company expects the workforce reduction will be substantially completed during the first quarter of 2026. The Company expects that it will incur approximately $4.5 million in costs in connection with the workforce reduction, which consist of severance and other one-time employee termination benefit expenses, which the Company expects to recognize primarily in the third and fourth quarters of 2025. The estimate of costs that the Company expects to incur, and the timing thereof, are subject to a number of assumptions and actual results may differ. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 17, 2025, the Company issued a press release providing an update on its collaboration with Pfizer, Inc. ("Pfizer") and announcing further actions to support value creation. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On September 17, 2025, the Company issued a press release providing an update on its collaboration with Pfizer and announcing further actions to support value creation, as discussed in additional detail below. Pfizer Collaboration Update The Company and Pfizer have jointly agreed to out-license the commercialization rights to vepdegestrant to a third party. Together, the companies have begun seeking a partner with the capabilities and expertise to maximize the commercial potential of vepdegestrant, if approved, for patients with estrogen receptor 1-mutant, estrogen receptor positive, human epidermal growth factor receptor 2 negative, advanced or metastatic breast cancer, and potentially develop vepdegestrant in new settings. Potential Value Creation In light of the change to the development plan for the vepdegestrant program and the Company's refocus on its early development programs, the Company has determined it will take further action to optimize organizational and cost structures and streamline operations in advance of multiple anticipated value inflection points in the coming months. These actions include: Further limiting additional expenditures on the vepdegestrant program to support activities required for commercialization readiness and identification and out-licensing of vepdegestrant to a third party for commercialization, subject to alignment with Pfizer; Reducing the Company's workforce by an additional 15% to streamline operations, with the most significant reductions being roles related to vepdegestrant commercialization; and Proactively managing pipeline cost by seeking strategic business development opportunities and by identifying further efficiencies across the business. The Company continues to believe that its cash, cash equivalents and marketable securities as of June 30, 2025, together with the actions described above, including the workforce reduction, will enable the Company to fund its planned operating exp

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release, da ted Septem b er 17 , 2025 . 104 Cover Page Interactive Data File (formatted as Inline XBRL) Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the potential out-license of vepdegestrant, limiting additional expenditures on the vepdegestrant program, the workforce reduction, management of pipeline costs, and purchases by the Company of its common stock pursuant a share repurchase program. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company's strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words "believe," "expect," "anticipate," "potentially," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements the Company makes as a result of various risks and uncertainties, including the important factors discussed the important factors discussed in the "Risk Factors" sections contained in the Company's quarterly and annual reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this Current Report on Form 8-K reflect the Company's current views with respect to future events, and the Company assumes no obligation to update any forward-looking statements except as required by applica

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARVINAS, INC. D ate: September 17, 2025 By: /s/ Andrew Saik Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR